The global tuberculosis drugs market size was valued at around USD 895.5 million in 2017 and is anticipated to exhibit a CAGR of 6.3% during the forecast period.
Tuberculosis is caused by the Mycobacterium tuberculosis bacterium. It spreads when a person with active TB coughs or sneezes and the bacteria come in contact with a healthy person. A weakened immune system is the key cause of tuberculosis prevalence. According to the Central for Diseases Control and Prevention, around one-fourth of the world's population is infected with TB. Further, TB is a vastly prevalent disease among people affected by HIV. According to the Centers for Disease Control and Prevention, in 2017, 10 million people suffered from TB around the globe. Treatments such as biological agents or chemotherapy that weaken the immune system further increases the chances of contracting tuberculosis.
|Market Size||USD 895.5 million in 2017|
|Fastest Growing Market||Asia Pacific|
|Largest Market||North America|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|
Geographically, the tuberculosis drugs market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa (LAMEA).
North America is projected to account for the largest share of the global tuberculosis drugs market during the forecast period, 2019–2026. Increasing prevalence of chronic diseases such as HIV diseases, which weaken the immune system is a key factor providing an impetus to the growth of the tuberculosis drugs market. According to the National Aids Control Organisation (NACO), in 2015, around 1.1 million people suffered from HIV.
Europe is expected to witness significant market growth during the forecast period, owing to the region’s sizable geriatric population. For instance, according to the U.K. Government, in 2017, around 579,776 people were older than 90 years.
Asia-Pacific is pegged to be the fastest growing market during the forecast period according to WHO, South-East Asia Region have the highest population around 45% of total population suffering from tuberculosis. Apart from that 82% of deaths reported among HIV negative people in South-East Asia Region in 2016. This increasing number of tuberculosis number in Asia-Pacific drives the tuberculosis drugs market.
The LAMEA region is expected to witness substantial market growth during the forecast period, owing to the increasing prevalence of tuberculosis and high disposable income in the Middle East.
The global tuberculosis drugs market can be segmented by disease type and therapy.
On the basis of disease type, the tuberculosis drugs market can be segmented into active TB and latent TB. The active TB segment is expected to dominate the market, due to the increasing incidences of DS and MDR TB cases. Based on therapy, the market can be segmented into first-line therapy and second-line therapy. Among the two, the second line therapy segment is expected to lead the market, owing to rising national surveillance efforts and global initiatives by WHO and Global Drug Facility (GDF).
In September 2018, QIAGEN N.V. and DiaSorin in collaboration launched automated, CE-marked workflow for QIAGEN’s QuantiFERON-TB Gold Plus Blood Collection Tubes (QFT-Plus BCT) and a novel DiaSorin LIAISON Test which is developed based on immunodiagnostic instruments from DiaSorin. Through this product launch, the company had expanded its product portfolio and Tuberculosis business in Europe